Table 2.

Prevalence of aspirin use for primary CVD prevention by select demographic characteristics, 2012–2015.

			Prevalence trend, 2012–2015
	Prevalencea	95% CI	Average annual rate of change, %	pb
All adults 40 +	22.1%	21.9–22.3	− 2.7%	0.003
Age group
40–49	9.8%	9.4–10.3	− 7.9%	0.001
50–64	24.0%	23.4–24.6	− 3.4%	0.023
≥ 65	35.0%	34.2–35.7	− 2.8%	0.050
Sex
Male	23.5%	23.2–23.8	− 3.3%	0.013
Female	20.8%	20.6–21.1	− 2.1%	0.099
Race
Non–Hispanic white	23.0%	22.8–23.3	− 4.3%	< 0.001
Non–Hispanic black	21.9%	21.5–22.4	5.1%	0.035
Hispanic	18.8%	18.3–19.3	4.0%	0.141
Other	18.3%	17.7–18.9	− 2.5%	0.497
Geographic region
Northeast	21.2%	20.7–21.7	− 2.1%	0.309
Midwest	23.4%	23.0–23.8	− 4.2%	0.015
South	22.6%	22.3–22.9	− 1.5%	0.323
West	21.0%	20.6–21.4	− 3.9%	0.067
Household income
$0–$34,999	20.7%	20.4–21.0	1.8%	0.235
$35,000–$74,999	22.8%	22.5–23.2	0.6%	0.760
$75,000–$99,999	23.5%	22.9–24.1	− 6.5%	0.028
$100,000 and over	24.1%	23.6–24.5	− 5.6%	0.009
Health insurance
Not covered	17.2%	16.0–18.4	− 4.8%	0.234
Covered	22.4%	22.2–22.6	− 3.4%	< 0.001
BMI
Underweight	13.9%	12.8–15.0	4.1%	0.633
Normal	18.5%	18.2–18.8	− 2.0%	0.272
Overweight	22.4%	22.1–22.7	− 2.8%	0.078
Obese	25.1%	24.8–25.4	− 3.7%	0.015
Education
< High school	17.4%	16.8–18.0	12.0%	0.002
High school	22.1%	21.8–22.4	− 0.4%	0.820
≥ College	22.9%	22.6–23.1	− 5.2%	< 0.001
Modifiable CVD risk factorsc
0	17.5%	17.2–17.9	− 5.0%	0.037
1	20.6%	20.3–20.9	− 5.6%	0.002
2	24.0%	23.6–24.4	− 2.7%	0.153
3	27.6%	27.1–28.2	0.4%	0.847
≥ 4	30.9%	30.1–31.6	0.4%	0.877

^aAge-adjusted to the 2000 standard US population.

^bp-Values are for trend significance via Wald F test, adjusted for age.

^cModifiable CVD risk factors include current smoking, diabetes, high cholesterol within the past year, hypertension within the past year, obesity, and physical inactivity.